SB-007 is an adeno-associated viral (AAV) vector gene therapy aimed at restoring expression of the full-length ABCA4 protein, and the only clinical-stage therapy with the potential to help all ...

This study explores speech-based personality prediction using deep learning, analyzing acoustic and linguistic features to ...

Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...

In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

BHUBANESWAR: In a significant medical breakthrough, India's first human gene therapy with a lentiviral vector for severe haemophilia-A has been found to be succ ...

Adds to Growing Portfolio of Intellectual Property AssetsATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a ...

A recent study published in the journal Human Gene Therapy evaluated the long-term survival and cardiac efficacy of the gene ...

A research group has discovered that in mammals, a protein kinase A (PKA) promotes wakefulness, while protein phosphatase 1 (PP1) and calcineurin promote sleep. This study revealed that the balance ...

AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today ...

Rocket Pharmaceuticals' gene therapy treatments for rare diseases are promising. See why I think high cash burn and potential ...